miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2

// Hyun Joo Chung 1, 2 , Young Eun Choi 1 , Eun Sook Kim 1, 2 , Young-Hoon Han 1 , Myung-Jin Park 1, 2 , In Hwa Bae 1, 2 1 Division of Radiation Cancer Research, Korea Institute of Radiological & Medical Sciences, Seoul, Korea 2 Research Center for Radio-Senescence, Korea Institute of Radiological & Medical Sciences, Seoul, Korea Correspondence to: In Hwa Bae, e-mail: ihbae@kirams.re.kr Keywords: miR-29b, BCL2L2, tumorigenicity, stemness, GBM Received: March 24, 2015      Accepted: June 09, 2015      Published: June 19, 2015 ABSTRACT Glioblastoma multiforme (GBM) is the most common malignant brain tumor and exhibits aggressive and invasive behavior. We previously identified four miRNAs—miR-29b, 494, 193a-3p, and 30e—with enhanced expression in GBM following treatment of ionizing radiation by miRNA microarray analysis. In this study, we found that only miR-29b inhibited tumor cell migration and invasion by reducing MMP-2 activity via phospho-AKT/β-catenin signaling, and stimulated a more epithelial-like morphology. Moreover, miR-29b inhibits angiogenesis by attenuating tube formation and the expression of VEGF and Ang-2, and stemness maintenance in GBM cells, as demonstrated by decreasing neurosphere formation and cancer stem cell marker protein expression. These findings support the anti-tumor properties of miR-29b in human GBM cells. Furthermore, miR-29b expression was inversely proportional to that of BCL2L2 mRNA or protein in various cancer cell types. Interestingly, BCL2L2 mRNA is highly expressed in the mesenchymal type of GBM. To further elucidate the relationship between miR-29b and BCL2L2 in GBM, we performed co-transfection reporter assays and determined that miR-29b downregulates BCL2L2 expression by directly binding its 3′UTR. Finally, we confirmed that BCL2L2 repression is of central importance to miR-29b anti-tumor activity using functional assays to examine cell migration, invasion, angiogenesis, and stemness. From these data, we propose that miR-29b may be a useful therapeutic agent in GBM.